Targeted therapies and immunotherapy can provide benefits when added to chemotherapy or may eliminate the need for chemotherapy in certain patients with NSCLC.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease. However, there ...

PARP inhibitors demonstrate synergy with radiation, so investigators tested the efficacy and safety of olaparib plus radium-223 in patients with mCRPC and bone metastases in a phase 2 trial.

Anti-EGFR therapies, such as cetuximab and panitumumab ... and randomized study enrolled 118 patients across 23 medical centers. Patients had colorectal cancer and developed moderate to severe ...

ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created from ALX Oncology’s proprietary linker-payload ...

23 Zappa C, et al. Non-small cell lung cancer ... Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. Abstract ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell ... reductions were recorded in 59% and 23% of patients in the two groups, respectively.

“Initial treatment with EGFR tyrosine kinase inhibitors has significantly ... Grade 3 or higher TRAEs occurred in 23% of patients. Adverse events of special interest (AESI) of any grade were ...

Patients with EGFR or ALK genomic tumor aberrations should ... reinitiated KEYTRUDA after symptom improvement; of these, 23% had recurrence. Pneumonitis resolved in 59% of the 94 patients.

Median PFS was 23.7 months (95% CI ... superior efficacy in the first-line treatment of certain patients with EGFR-mutated advanced NSCLC as shown with the MARIPOSA study,” said Alexander ...

In exchange, the U.K. pharma scores an exclusive option to license Pinetree’s preclinical EGFR degrader for global ... its founding in 2019, raising $23.5 million in a series A1 in June 2022.